Drug

Sino Biopharmaceutical's CTTQ Earns Dual CDE Breakthrough Therapy Designations for TQ-A3334 and TQA3605 in Chronic Hepatitis B
Breakthrough therapyChia Tai Tianqing Pharmaceutical

Sino Biopharmaceutical’s CTTQ Earns Dual CDE Breakthrough Therapy Designations for TQ-A3334 and TQA3605 in Chronic Hepatitis B

Sino Biopharmaceutical Limited (HKG: 1177) announced that TQ‑A3334 (a Toll-like receptor 7 agonist) and TQA3605 (a core protein allosteric modulator, CpAM), both Category 1 innovative drugs independently developed by its…

FDA Expands Pfizer's TALZENNA-XTANDI Approval to Earlier-Line HRR-Mutated Metastatic Prostate Cancer

FDA Expands Pfizer’s TALZENNA-XTANDI Approval to Earlier-Line HRR-Mutated Metastatic Prostate Cancer

Hengrui Wins NMPA Trial Clearance for First-in-Class SHR-2005 Combination in Bladder Cancer

Hengrui Wins NMPA Trial Clearance for First-in-Class SHR-2005 Combination in Bladder Cancer

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
Roche's Evrysdi 5mg Tablet Gains EU Commission Approval for Spinal Muscular Atrophy
OTCMKTS: RHHBYProduct approvals

Roche’s Evrysdi 5mg Tablet Gains EU Commission Approval for Spinal Muscular Atrophy

Sunshine Guojian's SSGJ-613 Meets Phase III Endpoints in Acute Gouty Arthritis
3SBioClinical trial filings

Sunshine Guojian’s SSGJ-613 Meets Phase III Endpoints in Acute Gouty Arthritis

Innovent Biologics' IBI363 Receives Breakthrough Therapy Designation from CDE
Breakthrough therapyHKG: 1801

Innovent Biologics’ IBI363 Receives Breakthrough Therapy Designation from CDE

BMS Secures NMPA Approval for Reblozyl in Myelodysplastic Syndromes
BMSBristol-Myers Squibb

BMS Secures NMPA Approval for Reblozyl in Myelodysplastic Syndromes

Show More